ArticleGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2026
Prognostic implications of tissue-based homologous recombination deficiency in metastatic gastric cancer treated with immune checkpoint inhibitor plus chemotherapy.
Article in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Computational prioritization of candidate TCDD-associated targets in retinoblastoma using network toxicology and transcriptomic analysis.Frontiers in genetics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundHomologous recombination deficiency (HRD), a genomic instability phenotype resulting from impaired DNA repair, has been associated with increased tumor immunogenicity in several solid tumors. However, its clinical relevance in metastatic gastric cancer (mGC), particularly in the context of immunotherapy-containing regimens, remains unclear.
methodsThis study included 139 GC patients with nivolumab plus chemotherapy as first line between May 2022 and May 2024 and underwent tissue-based NGS (n = 116); a smaller subset additionally underwent ctDNA-based NGS (n = 24). HRD was defined by the presence of pathogenic or likely pathogenic variants in predefined homologous recombination repair (HRR) genes. Treatment outcomes, and molecular characteristics were compared according to HRD status based on tissue- and/or circulating tumor DNA (ctDNA) NGS results.
resultsAmong 116 patients who underwent tissue-based NGS, HRD-positive tumors (14.7%) were significantly associated with longer progression-free survival (PFS; median 23.1 vs. 9.6 months; p = 0.032) to immune checkpoint inhibitor (ICI) plus chemotherapy and overall survival (OS; median not reached vs. 17.9 months; p = 0.027). HRD positivity remained an independent favorable prognostic factor for OS in multivariate analysis (HR: 0.247; 95% CI 0.071-0.859; p = 0.028). HRD-positive tumors showed higher frequencies of high tumor mutational burden (TMB) and microsatellite instability (MSI)-high tumors. However, exploratory analysis of ctDNA-based HRD in a small subset did not demonstrate a statistically significant association with survival outcomes.
conclusionTissue-based HRD positivity was associated with favorable survival outcomes and may provide complementary prognostic information in mGC patients with nivolumab plus chemotherapy as first line.
Indexed as
Identifiers
42171983What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.